Last reviewed · How we verify
Pneumococcal Conjugated Vaccine
A conjugated vaccine that stimulates the immune system to produce antibodies against pneumococcal polysaccharide antigens by linking them to a protein carrier.
A conjugated vaccine that stimulates the immune system to produce antibodies against pneumococcal polysaccharide antigens by linking them to a protein carrier. Used for Prevention of invasive pneumococcal disease in adults, Prevention of pneumococcal otitis media and pneumonia in children.
At a glance
| Generic name | Pneumococcal Conjugated Vaccine |
|---|---|
| Sponsor | Sanofi Pasteur, a Sanofi Company |
| Drug class | Conjugate vaccine |
| Target | Streptococcus pneumoniae capsular polysaccharides |
| Modality | Biologic |
| Therapeutic area | Immunology / Infectious Disease |
| Phase | Phase 3 |
Mechanism of action
Pneumococcal conjugated vaccines work by conjugating pneumococcal capsular polysaccharides to a protein carrier (such as CRM197 or diphtheria toxoid), which enhances immunogenicity and promotes T-cell dependent immune responses. This conjugation strategy improves antibody production and immunological memory compared to unconjugated polysaccharide vaccines, providing protection against invasive pneumococcal disease caused by the included serotypes.
Approved indications
- Prevention of invasive pneumococcal disease in adults
- Prevention of pneumococcal otitis media and pneumonia in children
Common side effects
- Injection site pain/erythema
- Fever
- Myalgia
- Fatigue
- Headache
Key clinical trials
- Influence of Methotrexate Discontinuation on Immunogenicity After PCV-20 Vaccine in Patients ARDs (PHASE4)
- Nasopharyngeal Carriage of S. Pneumoniae (NA)
- Safety, Tolerability, and Immunogenicity of VAX-31 in Adults ≥50 Years With Prior Pneumococcal Vaccination (PHASE3)
- Dose-Ranging Study to Evaluate a 25-Valent Pneumococcal Conjugate Vaccine (PHASE2)
- Safety, Tolerability, and Immunogenicity of VAX-31 in Adults ≥50 Years With Immunobridging to Adults 18-49 (PHASE3)
- Induction of Cross-protective Antibodies for Serogroup 33 by Pneumococcal Conjugate Vaccines (PHASE4)
- A Study to Understand the Safety of the 20vPnC Vaccine in Healthy Chinese Adults, Children, and Infant (PHASE1)
- A Study to Learn About the Safety of PREVENAR 20 Vaccine in Infants Aged Between Two to Six Months
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |